Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4- triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 7, 2010, Pages 908-911

  Catarzi, Daniela ^a   Lenzi, Ombretta ^a   Colotta, Vittoria ^a   Varano, Flavia ^a   Poli, Daniela ^a   Filacchioni, Guido ^a   Lingenhöhl, Kurt ^b   Ofner, Silvio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

(S) 2 amino 3 (3 hydroxy 5 methylisoxazol 4 yl) propionic acid; 3 hydroxyquinazoline; Anticonvulsant; Audiogenic seizure; Competitive antagonist; Triazoloquinoxaline

Indexed keywords

3 HYDROXYQUINAZOLINE 2,4 DIONE; 4,5 DIHYDRO 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CARBOXYLIC ACID DERIVATIVE; GLUTAMATE RECEPTOR 3; ISOXAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RECEPTOR SUBUNIT; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 3-HYDROXY-QUINAZOLINE-2,4-DIONE; ANTICONVULSIVE AGENT; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 3; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; ELECTROPHYSIOLOGY; MOUSE; NONHUMAN; OOCYTE; RECEPTOR AFFINITY; SEIZURE; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMISTRY; METABOLISM; RAT; SEIZURES; SYNTHESIS;

ANIMALS; ANTICONVULSANTS; MICE; OOCYTES; QUINAZOLINES; QUINOXALINES; RATS; RECEPTORS, AMPA; SEIZURES;

EID: 77954298451     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.908     Document Type: Article

References (44)

1. Dingledine R., Borges K., Bowie D., Traynelis S. F., Pharmacol. Rev., 51, 7-61 (1999).
2. Bräuner-Osborne H., Egebjerg J., Nielsen E. Ø., Madsen U., Krogsgaard-Larsen P., J. Med. Chem., 43, 2609-2645 (2000).
3. Foster A. C., Fagg G. E., Brain Res., 319, 103-164 (1984).
4. Komuro H., Rakic P., Science, 260, 95-97 (1993).
5. Mayer M. L., Westbrook G. L., Prog. Neurobiol., 28, 197-276 (1987).
6. Kew J. N. C., Kemp J. A., Psycopharmacology, 179, 4-29 (2005).
7. Johnson J. W., Ascher P., Nature (London), 325, 529-531 (1987).
8. Hollmann M., Heinemann S., Annu. Rev. Neurosci., 17, 31-108 (1994).
9. Millan M. J., Psycopharmacology, 179, 30-53 (2005).
10. Madden D. R., Nature Rev. Neurosci., 3, 91-100 (2002).
11. Wahlgren N. G., Int. Rev. Neurobiol., 40, 337-363 (1997).
12. Sellal F., Nieoullon A., Michel G., Michel B. F., Lacomblez L., Geerts H., Delini-Stula A., Bordet R., Bentué-Ferrer D., Allain H., Dementia Geriatr. Cognit. Disord., 19, 229-245 (2005).
13. Hynd M. R., Scott H. L., Dodd P. R., Neurochem. Int., 45, 583-595 (2004).
14. Hallett P. J., Standaert D. G., Pharmacol. Ther., 102, 155-174 (2004).
15. Corona J. C., Tovar-y-Romo L. B., Tapia R., Expert Opin. Ther. Targets, 11, 1415-1428 (2007).
16. Szèkely J. I., Török K., Màtè G., Curr. Pharm. Des., 8, 125-133 (2002).
17. Stone T. W., Addae J. I., Eur. J. Pharmacol., 447, 285-296 (2002).
18. Palmer C. L., Cotton L., Henley J. M., Pharmacol. Rev., 57, 253-277 (2005).
19. Bleakman D., Lodge D., Neuropharmacology, 37, 1187-1204 (1998).
20. Franciosi S., Cell. Mol. Life Sci., 58, 921-930 (2001).
21. Catarzi D., Colotta V., Varano F., Med. Res. Rev., 27, 239-278 (2007).
22. Loscher W., Wlaz P., Szabo L., Neurosci. Lett., 240, 33-36 (1998).
23. Rogawski M. A., Donevan S. D., Adv. Neurol., 79, 947-963 (1999).
24. Lees G. J., Drugs, 59, 33-78 (2000).
25. Auberson Y. P., Drugs Future, 26, 463-471 (2001).
26. De Sarro G., Gitto R., Russo E., Ferreri Ibbadu G., Barreca M. L., De Luca L., Chimirri A., Curr. Topics Med. Chem., 5, 31-42 (2005).
27. Meldrum B., Epilepsy Res., 50, 33-40 (2002).
28. Bourgeois B. F., Arch. Neurol., 55, 1181-1183 (1998).
29. Catarzi D., Colotta V., Varano F., Cecchi L., Filacchioni G., Galli A., Costagli C., J. Med. Chem., 42, 2478-2484 (1999).
30. Catarzi D., Colotta V., Varano F., Cecchi L., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 43, 3824-3826 (2000).
31. Catarzi D., Colotta V., Varano F., Filacchioni G., Galli A., Costagli C., J. Med. Chem., 44, 3157-3165 (2001).
32. Catarzi D., Colotta V., Varano F., Calabri F. R., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 47, 262-272 (2004).
33. Colotta V., Catarzi D., Varano F., Calabri F. R., Filacchioni G., Costagli C., Galli A., Bioorg. Med. Chem. Lett., 14, 2345-2349 (2004).
34. Colotta V., Catarzi D., Varano F., Lenzi O., Filacchioni G., Costagli C., Galli A., Ghelardini C., Galeotti N., Gratteri P., Sgrignani J., Deflorian F., Moro S., J. Med. Chem., 49, 6015-6026 (2006).
35. Honoré T., Drejer J., Nielsen E. O., Nielsen M., Biochem. Pharmacol., 38, 3207-3212 (1989).
36. Hollmann M., Hartley M., Heinemann S., Science, 252, 851-853 (1991).
37. Chapman A. G., Croucher M. J., Meldrum B. S., Arzneim.-Forsch., 34, 1261-1264 (1984).
38. Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J., Adv. Drug Deliv., 23, 3-25 (1997).
39. Veber D. F., Johnson S. R., Cheng H.-Y., Smith B. R., Ward K. W., Kopple K. D., J. Med. Chem., 45, 2615-2623 (2002).
40. Van de Waterbeemd H., Smith D. A., Beaumont K., Walker D. K., J. Med. Chem., 4, 1313-1333 (2001).
41. Kelder J., Grootenhuis P. D. J., Bayada D. M., Delbressine L. P. C., Ploemen J.-P., Pharmaceut. Res., 16, 1514-1519 (1999).
42. Steenland H. W., Kim S. S., Zhuo M., Eur. J. Neurosci., 27, 1166-1173 (2008).
43. Boelsterli U. A., Ho H. K., Khou S., Leow K. Y., Curr. Drug Metab., 7, 715-727 (2006).
44. Pozza M. F., Zimmen, K., Bischoff S., Lingenhoehl K., Prog. Neuropsychopharmacol. Biol. Psychiat., 24, 647-670 (2000).